A medical oncologist discusses the importance of CGP in cancer treatment decision-making, the need for efficient communication and support from test vendors, and current challenges with reimbursement. Clinical trial matching support is seen as beneficial, and biomarker testing should be included in CGP to avoid the need for multiple testing methods. They note that CGP is important for advanced stage tumors, especially those without defined markers. On a similar note, they also mention ongoing changes and additions to their CGP panel to accommodate rare mutations and clinical trial needs. The stakeholder acknowledges the reimbursement challenges associated with CGP testing and the need to limit the frequency of testing due to cost, highlighting the clinical utility of CGP as a pain point and suggesting that a blanket approach to testing may not be necessary. They suggest incorporating CGP into society guidelines and algorithms to ensure acceptance by payers and insurance companies. They also mention that newer technologies and AI can help reduce the turnaround time.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.